WuXi Biology: The Largest and a Unique Drug Discovery Biology Enabler
WuXi Biology is the only drug discovery biology enabler that meets all three criteria
WuXi Biology is also the world's
largest drug discovery biology enabling platform
WuXi Biology is well positioned to grow and ride the waves of
scientific breakthroughs
in biology
Drug Discovery Biology
Comprehensive
and end-to-end in discovery biology capability
Open access
Substantial
enabling platform
capacity and
outside of major
presence
pharma R&D
in Asia Pacific
organizations
2
Our Global Footprint
CHINA
Shanghai (WGQ)
Shanghai (Zhangjiang)
Suzhou
Nantong
Chengdu
UNITED STATES
GERMANY
Boston
Cranbury
San Diego
Munich
Leadership of WuXi Biology and Discovery Service Business Development
Steve Yang, PhD
Co-CEO & Head of WuXi Biology
Henry Lu, Ph.D.
Qunsheng Ji, Ph.D.
Xuanjia Peng, Ph.D.
Peiyuan Lin, Ph.D.
Declan Ryan, Ph.D.
Dave Madge, Ph.D.
Vice President,
Vice President,
Vice President,
GM of HD
Vice President,
Vice President,
Head of DBU
Head of OIU
Head of HitS
Biosciences
Discovery Service US
Discovery Service EU
Over 25 years'
Over 20 years' industry
Over 15 years' experience
Over 30 years'
BD Head
and Israel BD Head
experience and 20+
experience in drug
in organic/medicinal
experience in both drug
Over 20 years'
Over 30 years' drug
years' experience in
discovery and
chemistry, rich experience
discovery and the CRO
experience in R&D in
discovery experience in
anti-infective field.
translational science
on small molecule drug
industry.
both research and
pharma, biotech,
especially in oncology.
discovery.
business development
academia and CROs.
roles.
Robust and Continuous Business Growth
2016 - 2021 Revenue (￥M)
2016
2017
2018
2019
2020
E2021
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 20:30:09 UTC.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
WUXI APPTEC CO., LTD. 
